Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2020
FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer
23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 23 Jan 2020
The intricacies of rising drug prices in the US
23 January 2020 - Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what ...
Posted by Michael Wonder on 23 Jan 2020
Want to know how contentious drug pricing is in Washington? Check the receipts.
23 January 2020 - Pfizer, Johnson & Johnson, Merck, and the 31 other major drug makers that belong to the ...
Posted by Michael Wonder on 23 Jan 2020
Baudax Bio announces PDUFA date for intravenous meloxicam
22 January 2020 - Baudax Bio today announced that the U.S. FDA has set a PDUFA goal date of 20 ...
Posted by Michael Wonder on 23 Jan 2020
Sick of high drug prices, insurers join hospitals to make their own generic medications
23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...
Posted by Michael Wonder on 23 Jan 2020
Jazz Pharmaceuticals submits new drug application for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy
22 January 2020 - Jazz Pharmaceuticals today announced the submission of a new drug application to the U.S. Food and Drug ...
Posted by Michael Wonder on 22 Jan 2020
Supernus announces FDA acceptance for review of new drug application for SPN-812 for the treatment of ADHD
21 January 2020 - PN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent, demonstrates a reduction in ADHD-RS-5 total score ...
Posted by Michael Wonder on 22 Jan 2020
The FDA continues to struggle with the implications of approving Sarepta’s drugs
22 January 2020 - New documents released Wednesday lay bare the stark divide within the Food and Drug Administration regarding ...
Posted by Michael Wonder on 22 Jan 2020
Competition, not capping increases, is the cure for high drug prices
22 January 2020 - Soaring prescription drug prices are putting financial pressure on families across the country. ...
Posted by Michael Wonder on 22 Jan 2020
Supreme Court refuses to fast-track a challenge to the Affordable Care Act
22 January 2020 - The Supreme Court on Tuesday denied a motion to fast-track a challenge to the Affordable Care ...
Posted by Michael Wonder on 22 Jan 2020
FDA accepts Evoke Pharma’s NDA resubmission for Gimoti
21 January 2020 - PDUFA Target Goal Date is 19 June 2020. ...
Posted by Michael Wonder on 21 Jan 2020
FDA approves first treatment for thyroid eye disease
21 January 2020 - Today, the U.S. FDA approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a ...
Posted by Michael Wonder on 21 Jan 2020
Old drug, new tricks: existing medicines show promise in fighting cancer
20 January 2020 - Dozens of compounds approved for other purposes can kill cancer cells selectively. ...
Posted by Michael Wonder on 21 Jan 2020
Genprex receives U.S. FDA fast track designation for gene therapy that targets lung cancer
21 January 2020 - Genprex today announced that the U.S FDA has granted fast track Designation for Genprex’s Oncoprex immunogene ...